Memantine for the Long Term Management of Neuropsychiatric Symptoms in Alzheimer's disease (MAIN-AD).

Trial Profile

Memantine for the Long Term Management of Neuropsychiatric Symptoms in Alzheimer's disease (MAIN-AD).

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Jun 2016

At a glance

  • Drugs Memantine (Primary) ; Haloperidol; Olanzapine; Quetiapine; Risperidone
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms MAIN-AD
  • Most Recent Events

    • 30 Jan 2014 According to United Kingdom Clinical Research Network record accrual to date is 100%
    • 27 Oct 2011 Planned End Date changed from 15 Dec 2011 to 10 Jun 2011 as reported by United Kingdom Clinical Research Network record.
    • 27 Oct 2011 United Kingdom Clinical Research Network reports accrual to date changed from 62% to 100%.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top